{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3733, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "solution", "function": "present_solution", "notes": "Includes a B-cell development diagram and a human anatomy map linking specific diseases to medical specialties.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/6", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "pain_points", "function": "frame_problem", "notes": "The slide uses a hub-and-spoke diagram to connect a central problem (CAR-T Neurotoxicity) to four specific negative outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/7", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/8", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a diagram to map specific protein domains to their functional benefits.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/9", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "The slide uses external citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach of ITAM modification.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/10", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of the NXC-201 CD8 hinge optimization.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/11", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "solution", "function": "present_solution", "notes": "Includes a scientific quote justifying the use of Glycine/Serine linkers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/12", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a hub-and-spoke diagram to highlight four key clinical outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/13", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that these are not head-to-head results and caution should be exercised in comparison.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/14", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 6, "beatId": "1015cfcf-29ef-4d18-9dca-4c3f480cb602", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document presents the limitations of current treatment options and the challenges of neurotoxicity.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "unfair_advantage", "function": "present_solution", "notes": "The slide uses a biological diagram to illustrate the structural difference of the N-GENIUS platform compared to competitors like Abecma and Carvykti.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/15", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "solution", "function": "present_solution", "notes": "Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/16", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a visual timeline comparison to highlight the clinical advantage of NXC-201's shorter side-effect profile.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/17", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-day mark.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/18", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a bottom-up summation approach to define the total eligible patient pool.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/19", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a causal chain to link cellular pathology to systemic organ damage.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/20", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-20", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a bar chart to compare hematologic and cardiac response rates across different therapies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/21", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-21", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/22", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-22", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/23", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-23", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "roadmap", "function": "plan_implementation", "notes": "Includes a footnote citing FDA approval precedents for similar single-arm studies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/24", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-24", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Uses a visual icon-grid to represent market expansion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/25", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-25", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "Includes detailed clinical trial citations in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/26", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-26", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a two-column layout to separate milestones by drug candidate.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/27", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-27", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a standard pharmaceutical pipeline table format.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/28", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-28", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "why_now", "function": "argue_timing", "notes": "Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. Allogeneic CAR-T and Bispecifics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/29", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-29", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a stylized area chart to represent market segments and their respective valuations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/30", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-30", "loopMatches": [ { "to": 30, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5", "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.", "position": 0, "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/31", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-31", "loopMatches": [ { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The table uses a cross-trial comparison format. The red dashed box highlights the key clinical data rows.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/32", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-32", "loopMatches": [ { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/33", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-33", "loopMatches": [ { "to": 33, "from": 21, "name": "David Goliath", "slug": "16-david-goliath", "bestFor": "Startups, disruptive innovation, competitive displacement", "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18", "evidence": "The document presents clinical data and comparisons to existing therapies.", "position": 1, "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?", "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple", "confidence": 0.7, "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent" } ], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a side-by-side comparison of two disease indications, each with a list of clinical outcomes and a bottom section showing relevant market competitors and patient incidence numbers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/34", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-34", "loopMatches": [], "arcBeatMatches": [ { "to": 34, "from": 15, "beatId": "167b9d6c-4f69-438b-b991-0f1839680299", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "traction", "function": "show_traction", "notes": "The chart illustrates clinical trial efficacy data for NXC-201.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/35", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-35", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "solution", "function": "present_solution", "notes": "Includes a complex biological pathway diagram and three supporting charts (penetration depth, accumulation over time, and apoptosis efficacy).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/36", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-36", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a numbered list format to present key value propositions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/37", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-37", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/38", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-38", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a comparative layout to position NXC-201 as a superior, one-time monotherapy against current multi-drug, weekly treatment regimens.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/39", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-39", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide uses a step-wise process diagram to illustrate dose escalation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/40", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-40", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management of side effects.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/41", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-41", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide highlights specific safety data points for Arcellx's product, likely for competitive benchmarking purposes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/42", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-42", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "comparison_table", "function": "compare_peers", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/43", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-43", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table compares clinical trial inclusion criteria across four different therapies, focusing on prior lines of therapy, toxicity recovery, ECOG status, and measurable disease definitions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/44", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-44", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/45", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-45", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 46, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a bar chart to contrast the combined market size of two groups of drugs ($33.4bn vs $0.9bn).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/46", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-46", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "traction", "function": "show_traction", "notes": "Slide contains three distinct data charts comparing IMX-110 against standard treatments in mouse models.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/47", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-47", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 48, "slideType": "traction", "function": "show_traction", "notes": "Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/48", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-48", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 49, "slideType": "traction", "function": "show_traction", "notes": "Includes unpublished internal data alongside referenced Winograd et al. 2015 study.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/49", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-49", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 50, "slideType": "traction", "function": "show_traction", "notes": "The slide compares two cohorts: Soft Tissue Sarcoma and Non-Sarcoma Cancers, using line charts for longitudinal change and bar charts for best response.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/50", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-50", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 51, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a bubble chart to map clinical trial outcomes and a table to detail specific drug performance metrics across treatment lines.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/51", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-51", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 52, "slideType": "traction", "function": "show_traction", "notes": "The chart on the left is a conceptual visualization rather than a standard data plot, emphasizing the 100% heavily pre-treated patient population.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/52", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-52", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 53, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a process flow diagram to illustrate the clinical development path for two different treatment regimens.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/53", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-53", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 54, "slideType": "solution", "function": "present_solution", "notes": "Includes comparative size illustration of IMX-111 vs IgG antibody, and survival curve data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/54", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-54", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 55, "slideType": "traction", "function": "show_traction", "notes": "Includes two sets of charts: tumor volume over time and survival curves for two different cancer models.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/55", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-55", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 56, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a mix of mechanism-of-action diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/56", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-56", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 57, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/57", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-57", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 58, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a side-by-side comparison structure to explain two distinct but complementary proprietary platforms.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/58", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-58", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 59, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/59", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-59", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 60, "slideType": "roadmap", "function": "plan_implementation", "notes": "The process flow is non-linear, moving left-to-right on the top row (1-5) and right-to-left on the bottom row (6-10).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/60", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-60", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 61, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a 3-pillar framework to explain the platform, then maps these to specific drug candidates with detailed mechanism-of-action descriptions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/61", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-61", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5", "docSlug": "225408061c3ed04b028031d27cf2467f", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides", "authorId": "immix-biopharma", "authorName": "ImmixBio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 62, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/62", "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5", "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-62", "loopMatches": [], "arcBeatMatches": [ { "to": 62, "from": 35, "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7f75-7018-9745-0295f8cc0604", "docSlug": "ff20cbe040f7db4fd450e0597505890e", "documentTitle": "Innovid | Investor Day Presentation Deck | 74 slides", "authorId": "innovid", "authorName": "Innovid", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/csadAQsxrdkXeU3WSIWlMFysOjr6OXrDItrJMJBfxv4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mZjIwY2JlMDQwZjdkYjRmZDQ1MGUwNTk3NTA1ODkwZS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7f75-7018-9745-0295f8cc0604/1", "deckHref": "/decks/019de076-7f75-7018-9745-0295f8cc0604", "deckAnchorHref": "/decks/019de076-7f75-7018-9745-0295f8cc0604#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/np4ZR3L75KxrkCWWRppHwN163qrRJV-Jj2efbT6ic4A/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mZjIwY2JlMDQwZjdkYjRmZDQ1MGUwNTk3NTA1ODkwZS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/5Gxfn_IHPB48tV81suw6sRVciymVRaOZnIDUDlu6fvg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mZjIwY2JlMDQwZjdkYjRmZDQ1MGUwNTk3NTA1ODkwZS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/l6uvdj7UbgX2FKgNZsvJ_deEvmBD0nSiV9DnJeNNk9c/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mZjIwY2JlMDQwZjdkYjRmZDQ1MGUwNTk3NTA1ODkwZS9wMDAxLnBuZw" }, { "docId": "019de076-7f75-7018-9745-0295f8cc0604", "docSlug": "ff20cbe040f7db4fd450e0597505890e", "documentTitle": "Innovid | Investor Day Presentation Deck | 74 slides", "authorId": "innovid", "authorName": "Innovid", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7f75-7018-9745-0295f8cc0604/2", "deckHref": "/decks/019de076-7f75-7018-9745-0295f8cc0604", "deckAnchorHref": "/decks/019de076-7f75-7018-9745-0295f8cc0604#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-7f75-7018-9745-0295f8cc0604", "docSlug": "ff20cbe040f7db4fd450e0597505890e", "documentTitle": "Innovid | Investor Day Presentation Deck | 74 slides", "authorId": "innovid", "authorName": "Innovid", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-7f75-7018-9745-0295f8cc0604/3", "deckHref": "/decks/019de076-7f75-7018-9745-0295f8cc0604", "deckAnchorHref": "/decks/019de076-7f75-7018-9745-0295f8cc0604#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }